VetCell Bioscience’s pioneering stem cell technique, which is used to return injured horses to top levels of performance, will be tested in human medicine. The trials will be conducted by VetCell’s parent company MedCell Bioscience Ltd under the guidance of David Glover, MD, former medical director of Cambridge Antibody Technologies, Professor Nicola Maffulli, MD, MS, PhD, FRCS(Orth), one of the most pre-eminent sports medicine and orthopaedic consultants in the U.K., and Roger Smith, MA, VetMB, DEO, MRCVS, PhD, Dipl. ECVS, professor of Equine Orthopaedics at The Royal Veterinary College.

The therapeutic approach implants millions of the patient’s own stem cells, growth factors, and an autologous scaffold directly into the injured tendon or ligament. More than 1,500 horses have been treated to date, and follow-up data suggests a 50% reduction in reinjury over a three year period, compared to conventionally treated horses